Informações:
Falhas:
ID
34204
Descrição
RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab; ODM derived from: https://clinicaltrials.gov/show/NCT01943786
Link
https://clinicaltrials.gov/show/NCT01943786
Palavras-chave
Versões (1)
- 15/01/2019 15/01/2019 -
Titular dos direitos
see on clinicaltrials.gov
Transferido a
15 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Colorectal Cancer Metastatic NCT01943786
Eligibility Colorectal Cancer Metastatic NCT01943786
- StudyEvent: Eligibility
Similar models
Eligibility Colorectal Cancer Metastatic NCT01943786
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
diagnosis of stage iv colorectal adenocarcinoma.
boolean
ID.2
Item
patient ≥ 18 years of age.
boolean
ID.3
Item
ecog ps 0-1
boolean
ID.4
Item
life expectancy ≥ 6 months
boolean
ID.5
Item
candidate for first-line systemic chemotherapy according to regular clinical practice.
boolean
ID.6
Item
measurable disease.
boolean
ID.7
Item
wild-type kras
boolean
ID.8
Item
signed informed consent form.
boolean
ID.9
Item
patient who has received prior chemotherapy for metastatic crc, except for adjuvant treatment completed at least six months before entering study.
boolean
ID.10
Item
patient in whom there is a contraindication for the use of any of the drugs used in first-line treatment of colorectal cancer: 5-fluorouracil,, irinotecan or cetuximab
boolean